Clinical trial · Interventional
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor
NCT00007982CI-TRIAL-00009273completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well chemotherapy and peripheral stem cell transplant work in treating patients with central nervous system cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| autologous bone marrow transplantation | Procedure | — | UNRESOLVED |
| bone marrow ablation with stem cell support | Procedure | — | UNRESOLVED |
| carmustine | Drug | Carmustine | ALIAS |
| cisplatin | Drug | Cisplatin | ALIAS |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| filgrastim | Biological | Filgrastim | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Response rate
- measure
- Disease-free suvival
- measure
- Overall survival
- measure
- Toxicity
- measure
- Quality of life
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed malignant tumors
* Anaplastic astrocytoma
* Oligodendroglioma
* Germ cell tumor
* Medulloblastoma
* Primary neuroectodermal tumor
* Esthesioneuroblastoma
* CNS lymphoma (primary or systemic disease)
* Multifocal intracranial disease allowed
* No extraneural metastases (except controlled systemic lymphoma)
* Pretreatment considerations based on tumor type
* Anaplastic astrocytoma:
* Recurrent disease
* Any treatment at diagnosis allowed (carmustine dose limited to 480 mg/m2)
* Chemotherapy not required at recurrence
* Oligodendroglioma:
* Disease response (at least minor) to conventional chemotherapy OR
* Recurrent disease
* Esthesioneuroblastoma:
* Attempted complete surgical resection
* Disease progression after radiotherapy
* Response to chemotherapy regimen comprising cyclophosphamide, etoposide, and cisplatin
* CNS lymphoma:
* Disease refractory to methotrexate OR
* Failure after initial treatment with methotrexate OR
* Considered at high risk for disease relapse despite initial response
* Radiographic or pathological confirmation of recurrent disease required
* Not eligible for other high priority national or institutional clinical studies
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG or Zubrod 0-1
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Creatinine less than 1.5 times normal
Cardiovascular:
* LVEF at least 45%
Pulmonary:
* DLCO at least 60% predicted OR
* Approval of pulmonologist
Other:
* Not pregnant or nursing
* HIV negative
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* See Disease Characteristics
* No other concurrent chemotherapy
Endocrine therapy:
* No concurrent anticancer hormonal therapy
* No concurrent steroids as antiemetics
Radiotherapy:
* See Disease Characteristics
Surgery:
* See Disease Characteristics
Other:
* No concurrent barbiturates or acetaminophen
* Participation in other concurrent supportive care or gene therapy trials allowedReferences
Publications (0)
Data not yet available
No reference posted for this study.